Evidence map›Paper›PMID 41913793›Full record

ArticleJournal of inflammation research2026

Huazhuo Decoction Contributes to Immune Homeostasis and Attenuates Neuronal Inflammation and Demyelination in a Mouse Model of Multiple Sclerosis.

Jing-Ying Wu, Juan Zhang, Shan Xu, Shi-Yan Qian, Zheng Zha, Jia-Ling Hu, Jiang-Li Yang, Feng-Xia Zhang, Guo-Qing Zheng

Abstract read
In one paragraph

Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jing-Ying Wu *Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, People's Republic of China.ORCID 0009-0000-3989-0619
Juan Zhang *Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, People's Republic of China.
Shan Xu *Department of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, People's Republic of China.
Shi-Yan QianDepartment of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, People's Republic of China.
Zheng ZhaDepartment of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, People's Republic of China.
Jia-Ling HuDepartment of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, People's Republic of China.
Jiang-Li YangDepartment of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, People's Republic of China.
Feng-Xia ZhangDepartment of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.ORCID 0000-0002-9574-8155
Guo-Qing ZhengDepartment of Neurology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS). Huazhuo decoction (HD) has been shown to ameliorate disease progression in MS patients, but the underlying mechanisms remain poorly understood. Purpose: This study sought to assess the therapeutic efficacy of HD in an experimental autoimmune encephalomyelitis (EAE) model of MS, and to further investigate the underlying mechanisms involved. Methods: We assessed the curative effects of HD on EAE mice via neurological function scoring and histological staining and identified the chemical composition of HD by UPLC-MS. RNA sequencing identified differentially expressed genes. Flow cytometry detected the proportions of splenic Th17, Th1, and Treg cells. Expression of key molecules was evaluated by Western blotting and quantitative PCR. Immunofluorescence was used to monitor microglia, astrocytes and oligodendrocytes. Results: HD alleviated neurobehavioral impairment, inflammatory infiltration and demyelination in EAE mice. RNA sequencing revealed that HD may ameliorate EAE by modulating adaptive immunity and affecting NLRP3-related signaling pathways. Further studies demonstrated that HD suppressed the upregulation of NF-κB/NLRP3 pathway, balanced the proportions of peripheral Th17, Th1 and Treg cells and regulated inflammatory cytokines. HD influenced innate immunity by reducing microglia and astrocytes and increasing oligodendrocytes in the CNS. Notably, these protective effects of HD were attenuated by an NLRP3 agonist. Conclusion: HD effectively alleviated the clinical symptoms of EAE mice and inhibited both peripheral and central immune inflammatory responses by modulating the NF-κB/NLRP3 pathway, providing a strong basis for its clinical application.

Indexed as

Huazhuo decoctionmultiple sclerosisneuroinflammationNLRP3regulatory T cellTh17 cell

Identifiers

PMID41913793
PMCPMC13033261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.